Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2020-12-22 Legal Proceedings Report
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
Legal Proceedings Report Classification · 99% confidence The document is titled as a press release and contains a headline announcing a clinical trial milestone ('Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study') and expected results timeline ('Topline results expected in Q3 2021'). It includes quotes from the Chief Medical Officer and details about the clinical study, which are typical components of an Earnings Release (ER) or a general press release regarding operational updates. Since it is an announcement of operational progress and expected future results, rather than a full financial report (10-K, IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often accompany or precede formal financial reporting periods with key operational highlights. It is not a Call Transcript (CT), Audit Report (AR), Annual Report (10-K), or a simple Report Publication Announcement (RPA) because it contains substantive operational news, not just a notice that a report is available. It is a direct announcement of a significant operational event.
2020-12-22 English
Bone Therapeutics finalise le recrutement et le traitement des patients dans son étude pivot de Phase III évaluant le JTA-004 dans l’arthrose du genou
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE" (Press Release – Regulated Information) and announces a major operational milestone: the completion of patient recruitment for a Phase III clinical study (JTA-004 for knee osteoarthritis). It provides key updates, expected result timelines (Q3 2021), and context about the drug and the trial. This format—a formal, timely announcement of a significant corporate/clinical event, often released via regulatory channels—best fits the definition of an Earnings Release (ER) if it were financial results, but since it is a clinical/operational update, it is most accurately classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company typically bundles operational updates with financial reporting announcements. Given the focus is purely on clinical trial progress and not quarterly financial figures, and it is labeled as 'Information Réglementée' (Regulated Information), it functions as a broad regulatory disclosure. Since there is no specific code for 'Clinical Trial Update', RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate category, as it is a formal, time-sensitive disclosure to the market.
2020-12-22 French
Bone Therapeutics _Private Placement 2020_Rapport special BoD_signe.pdf
Capital/Financing Update Classification · 99% confidence The document is titled "RAPPORT SPECIAL DU CONSEIL D'ADMINISTRATION ETABLI CONFORMENT AUX ARTICLES 7:198 JUNCTO ARTICLES 7:191 ET 7:193 DU CODE DES SOCIETES ET ASSOCIATIONS" (Special Report of the Board of Directors established in accordance with Articles 7:198 juncto Articles 7:191 and 7:193 of the Companies and Associations Code). It details a proposal by the Board to increase the company's capital through a private placement, explicitly justifying the suppression of existing shareholders' preferential subscription rights as required by Belgian corporate law (CSA articles). This document serves as a detailed report to shareholders regarding a specific corporate action involving capital structure changes and the issuance of new shares, which aligns closely with the description of a document detailing capital/financing activities and related legal justifications. While it involves a share issue (SHA), the primary nature of this specific document is the legally mandated report justifying the suppression of pre-emption rights for a capital increase, making it a specialized report on capital structure changes. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it directly concerns a proposed capital increase via private placement, although it is a formal report rather than a simple announcement. Since it is a comprehensive report detailing the structure, justification, and participants of a capital raise, CAP is preferred over SHA (which is usually the announcement of the issue itself) or RPA (which is an announcement *about* a report). The length (over 34k characters) confirms it is the report itself, not just a brief announcement.
2020-12-11 French
Bone Therapeutics announces pricing of private placement
Capital/Financing Update Classification · 98% confidence The document is explicitly titled as a "PRESS RELEASE - REGULATED INFORMATION" dated December 11, 2020. The core subject is the announcement of a private placement of new shares, detailing the pricing (EUR 2.25 per share), gross proceeds (approximately EUR 10 million), and the intended use of proceeds (funding clinical trials and operations). This activity directly relates to fundraising, financing activities, and capital structure changes (issuance of new shares). This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it involves share issuance, the primary focus is the financing event itself, rather than just a general share issue announcement (SHA) or a transaction in own shares (POS). Since it is a formal announcement detailing a capital raise, CAP is the most appropriate classification.
2020-12-11 English
Bone Therapeutics réalise un placement privé
Capital/Financing Update Classification · 98% confidence The document is explicitly titled 'COMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE' (Press Release – Regulated Information) dated December 11, 2020. The core content announces that 'Bone Therapeutics réalise un placement privé' (Bone Therapeutics completes a private placement) to raise approximately 10 million euros through the issuance of new shares. This action directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (Code: CAP). Although it is a press release, its specific subject matter (fundraising via share placement) is more precise than the general 'RPA' or 'RNS' fallback categories.
2020-12-11 French
Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent
M&A Activity Classification · 99% confidence The document is titled "Bone Therapeutics announces completion of the acquisition of its cell therapy manufacturing subsidiary SCTS by Catalent" and is explicitly labeled as a "PRESS RELEASE - REGULATED INFORMATION". It details a specific corporate transaction (acquisition/divestiture) involving the sale of a subsidiary for a specific cash consideration (€12 million gross proceeds). This type of announcement, detailing a significant corporate event like an acquisition or divestiture, is generally classified as a major corporate action announcement. While it is a form of regulated information, it is more specific than a general RNS. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since there is no specific code for M&A activity or corporate transaction announcements, and given the nature of the announcement (a significant, non-financial-result-focused corporate event), it fits best under the general 'Regulatory Filings' (RNS) category as a catch-all for significant, non-standard announcements, or potentially 'TAR' (M&A Activity) if the scope was broader, but this is a completion announcement of a previously announced transaction. Given the options, and since it's a press release about a transaction, RNS is the safest general regulatory filing category, although TAR (M&A) is also plausible. However, since the core event is the completion of an acquisition/divestiture, and TAR is defined as 'Merger Proposals or Takeover Bids', this announcement of completion fits the spirit of M&A activity. I will classify it as TAR as it directly relates to a transaction involving the transfer of a business unit.
2020-11-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.